CITY OF HOPE

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
星期一, 五月 6, 2024
PSMA, FDA, Net, University, Part, DLBCL, EDT, City, CRS, Safety, PIN, University of Miami, Pancreatic cancer, Infrared spectroscopy correlation table, Research, Hematology, Insurance, PR, MD, Growth, ICU, Rituximab, Follicular lymphoma, ADC, Patient, Therapeutic index, Sarcoma, S&M, Diffuse large B-cell lymphoma, NHL, Cytokine release syndrome, Marketing, IIT, Advertising, Therapy, NSCLC, Spacecraft, AXL, Lung cancer, Pharmaceutical industry

Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.

Key Points: 
  • Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.
  • Net product revenues were $17.8 million for the first quarter 2024, compared to $19.0 million for the first quarter 2023.
  • R&D expenses were $25.7 million for the first quarter 2024, compared to $38.4 million for the first quarter 2023.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss first quarter 2024 financial results and provide a company update today at 8:30 a.m. Eastern Time.

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Retrieved on: 
星期一, 五月 6, 2024
FDA, University, City, Safety, University of Miami, Doctor of Philosophy, ADC, Patient, Diffuse large B-cell lymphoma, NHL, Toxicity, Therapy, Pharmaceutical industry

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).

Key Points: 
  • LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).
  • As of the data cutoff date of March 30, 2024, 15 patients were evaluable.
  • Of these 15 patients evaluated, 13 achieved a complete response (CR) and one patient achieved a partial response (PR).
  • “Based on the initial data from University of Miami’s Phase 2 trial evaluating ZYNLONTA in relapsed/refractory MZL, we are encouraged by the potential opportunity in the 2L+ setting for patients with this rare disease.”

Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort

Retrieved on: 
星期一, 四月 15, 2024
Cancer, Bile, FDA, Imugene, City, IMU, Immunotherapy, Recurrence, Breast, ASX, Conference, Thymic carcinoma, Disease, Patient, MAST, Lung, Pharmaceutical industry

Cholangiocarcinoma is a rare disease in which malignant cancer cells form in the bile ducts.

Key Points: 
  • Cholangiocarcinoma is a rare disease in which malignant cancer cells form in the bile ducts.
  • On Friday 12 April 2024, the Cohort Review Committee cleared the fifth cohort in the IT arm of the monotherapy dose escalation portion of the MAST trial, with no safety signals seen to date.
  • In addition to the patients dosed in the monotherapy dose escalation portion of the trial, enrolment is ongoing for the VAXINIA and pembrolizumab combination portion of the trial, with 16 patients dosed to date.
  • With no safety signals identified to date, the trial has since progressed through the monotherapy dose escalation cohorts as well as the combination study, whereby VAXINIA is administered with well-known checkpoint inhibitor pembrolizumab.

Nine-year-old Southern California Leukemia Survivor Will Meet Donor Who Saved Her Life at City of Hope’s Bone Marrow Transplant Reunion

Retrieved on: 
星期二, 四月 30, 2024
Oncology, Philanthropy, Health, Hospitals, Foundation, Research, Science, BMT, Bone marrow, Cancer, Patient, Multiple myeloma, Chronic myelomonocytic leukemia, City, Blood, Parent, Leukemia, Medicine, Life, Female, B cell, Lymphoma, Family, Transplant, Child, HIV, CIM, Fever, Longevity, Wang, Dentistry

On Friday, May 3, at a 10 a.m. press conference on the cancer center’s Duarte, California, campus, Tammy and her family will meet her donor for the first time at City of Hope’s 48th Annual Bone Marrow Transplant (BMT) Reunion.

Key Points: 
  • On Friday, May 3, at a 10 a.m. press conference on the cancer center’s Duarte, California, campus, Tammy and her family will meet her donor for the first time at City of Hope’s 48th Annual Bone Marrow Transplant (BMT) Reunion.
  • Early support from its philanthropic partners helped City of Hope become a leader and pioneer with bone marrow transplant and have ensured the program’s longevity and success.
  • City of Hope has exceptional survivor rates year after year, according to the Center for International Blood and Marrow Transplant Research.
  • In addition to Tammy and her family meeting her donor, Southern California resident Terry Greene, 71, who survived chronic myelomonocytic leukemia, will also meet his international donor, a 24-year-old college student.

AccessHope Secures $33 Million in Series B Funding to Expand Access to Leading Cancer Expertise

Retrieved on: 
星期一, 四月 22, 2024
UnitedHealth Group, Cancer, Emory Healthcare, City, Sidney Kimmel, Johns Hopkins, Business development, National Cancer Institute, Winship Cancer Institute, Growth, Policy, Patient, Blackstone Inc., Acquisition, NCI, Medicare, Emory University, Health, Dana–Farber Cancer Institute, Pharmaceutical industry

DUARTE, Calif., April 22, 2024 /PRNewswire/ -- AccessHope, LLC, a company changing the way leading-edge cancer expertise is delivered, today announced that it has raised $33 million in a Series B round of funding from City of Hope, one of the largest cancer research and treatment organizations in the United States. AccessHope's next phase of growth as a stand-alone company will include product and technology development, oncology network expansion and entering new markets, such as health plans, Medicare and government organizations.

Key Points: 
  • To lead its transformation into a commercial business, AccessHope appointed seasoned healthcare, payer and investment veteran Bradley Kreick as its new CEO.
  • Kreick, who has served on the AccessHope board since 2023, brings 30 years of experience leading companies through periods of significant growth.
  • "AccessHope was founded with the mission of bringing cutting-edge cancer care knowledge to the places and people who need it most.
  • Through these collaborations, AccessHope members now have access to expertise from more than 350 of the world's top oncologists, covering all cancer types and stages.

AMD Lead Independent Director Nora Denzel and Best Buy Board Chair-Elect David Kenny to Co-Chair the 2024 NACD Blue Ribbon Commission on Board Oversight of Technology

Retrieved on: 
星期二, 四月 16, 2024
NACD, City, Toyota, Vanguard, Tufts University, Pentair, Business, Intelligence, Harvard Business School, Chairperson, SIPA, The Weather Company, CSX Corporation, HPE, AMD, Trust, Asurion, Nashville Electric Service, Sally Beauty Holdings, General Atlantic, Blue-ribbon committee, CIO, Head, Weather Underground (weather service), RET, ServiceNow, United States Air Force, International, Consumer, General counsel, Blockchain, Advisory board, Research, Artificial intelligence, Commission, Drexel University, World Economic Forum, Booking Holdings, Former, UMB, Akamai Technologies, Organization, Weather, Public affairs, UMB Financial Corporation, Quest Diagnostics, Gen, Senior, Intuit, Innovation Hub, Growth, IBM, Management

WASHINGTON, April 16, 2024 /PRNewswire/ -- NACD today announced it has appointed a commission to examine board oversight of technology, prompted in part by the emergence of disruptive technologies like generative artificial intelligence which are impacting all business operations. The 2024 NACD Blue Ribbon Commission will be spearheaded by the following co-chairs:

Key Points: 
  • The 2024 NACD Blue Ribbon Commission will be spearheaded by the following co-chairs:
    Nora Denzel , NACD.DC™, Lead Independent Director, Advanced Micro Devices, Director, Gen Digital and NACD, and Former C-suite Technology Executive at Intuit, HPE and IBM.
  • David Kenny , Board Chair-Elect, Best Buy, Executive Chair, Nielsen and former CEO of Digitas, Akamai, Publicis, The Weather Company and Nielsen.
  • Directors cited the increasing pace of technological change as a top priority for 2024 in the most recent NACD Directors Outlook .
  • David Kenny , Board Chair-Elect, Best Buy; Executive Chair, Nielsen; and former CEO of Digitas, Akamai, Publicis, The Weather Company and Nielsen.

PRIVACY ALERT: City of Hope Under Investigation for Data Breach of 827,000 Patient Records

Retrieved on: 
星期五, 四月 12, 2024
Roger Hawkins (drummer), Social Security, Social, LLP, City, Identity theft, Risk, Computer, Patient, Privacy, Name, SAN

According to the company, an unauthorized third party accessed a subset of City of Hope's computer systems between September 19 and October 12, 2023 and copied files.

Key Points: 
  • According to the company, an unauthorized third party accessed a subset of City of Hope's computer systems between September 19 and October 12, 2023 and copied files.
  • If your personal information was impacted by this incident, you may be at risk of identity theft, healthcare or financial fraud, and other serious violations of your privacy.
  • As a result, you may be entitled to money damages and an injunction requiring changes to City of Hope's cybersecurity practices.
  • If you received notification of this data breach or are a patient of City of Hope and want additional information about your legal rights, please contact us today or visit our website at https://www.classactionlawyers.com/cityofhope .

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

Retrieved on: 
星期四, 四月 11, 2024
FDA, University, City, Index, Tumor microenvironment, Doctor of Philosophy, National Cancer Institute, Research, Transplant, Lymphoma, Biologics license application, Oncology, COH, Patient, NCI, BCL, UMN, University of Minnesota, Division, Pharmaceutical industry

CRANFORD, N.J., April 11, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the University of Minnesota Masonic Cancer Center intends to expand their ongoing investigator-initiated Phase 1 trial of LYMPHIR™ (denileukin diftitox) in combination with FDA-approved CAR-T products for the treatment of B-cell lymphomas. The ongoing study, led by Dr. Veronika Bachanova at the University of Minnesota (UMN), will include an additional study site at City of Hope (COH), a world-renowned cancer treatment and research institution, with Dr. Matthew Mei as the principal site investigator at COH. City of Hope is one of only 53 National Cancer Institute (NCI)-designated comprehensive cancer centers in the U.S.

Key Points: 
  • "This first-of-its-kind study will evaluate the potential value that transient depletion of T-regs within the tumor microenvironment by LYMPHIR has upon CAR-T-based anti-tumor activity," added Dr. Czuczman.
  • "This trial is designed to augment lymphodepletion prior to CAR-T cells by administration of targeted immunotoxin against IL-2 receptor-positive regulatory T-cells.
  • Citius is collaborating with the University of Minnesota (UMN) in this investigator-initiated study.
  • Enrollment is underway for patients diagnosed with relapsed or refractory BCL, for which treatment with CAR-Ts is planned, and who are considered at high risk for progression after CAR-T therapy.

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 

Retrieved on: 
星期一, 四月 8, 2024
Principal, Malignancy, Risk, Patient, Food and Drug Administration, City, CRS, NHL, Mutagenesis, Therapy, Hematology, Bone marrow, B-cell lymphoma, APOLLO, Neurotoxicity, DLBCL, Cytokine release syndrome, Lymphoma, Press release

HOUSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada (April 2-7, 2024). Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.

Key Points: 
  • Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.
  • During the presentation, Dr. Shouse showed that this study participant remains in CR nine months following initial treatment with MT-601.
  • This APOLLO participant had diffuse large B cell lymphoma (DLBCL) and failed four prior lines of therapy, including anti-CD19 CAR T cell therapy.
  • Dr. Shouse’s presentation included data from two additional study participants that have been treated at City of Hope.

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Customers Whose Personal Data May Have Been Compromised By The City of Hope Data Breach

Retrieved on: 
星期五, 四月 5, 2024
Social Security, Privacy, City, Social, Computer, HERE, LLP

NEWTOWN, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating claims regarding data privacy violations by City of Hope, a cancer hospital and research center.

Key Points: 
  • NEWTOWN, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating claims regarding data privacy violations by City of Hope, a cancer hospital and research center.
  • City of Hope learned of suspicious activity on or about October 13, 2023.
  • On or about October 13, 2023, City of Hope detected suspicious activity on its computer systems and took immediate action to contain it.
  • Edelson Lechtzin LLP is investigating bringing a class action lawsuit to seek legal remedies on behalf of customers who may have had their sensitive personal and patient data compromised by the City of Hope data breach.